<DOC>
	<DOCNO>NCT00950066</DOCNO>
	<brief_summary>The primary objective compare extent reduction mean Seated Diastolic Blood Pressure ( SeDBP ) end 8 week Fixed Dose Combination ( FDC ) , individual constituent administer monotherapy placebo . The secondary objective : - compare reduction mean Seated Systolic Blood Pressure ( SeSBP ) end 8 week baseline FDC , individual constituent administer monotherapy placebo . - compare reduction mean SeDBP SeSBP 4 week baseline FDC , individual constituent administer monotherapy placebo .</brief_summary>
	<brief_title>Irbesartan Amlodipine Combination Controlling Blood Pressure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criterion : Subjects uncomplicated mild moderate essential hypertension ( per European Society Cardiology Classification Hypertension ) Treatment naïve subject ( newly diagnose subject subject currently lifestyle modification ) mean SeDBP 95 109 mmHg screen randomization visit ( mean 3 recording interval 1 minute ) Or Uncontrolled antihypertensive monotherapy mean SeDBP 90 109 mmHg screen mean SeDBP 95 109 mmHg randomization visit ( mean 3 recording interval 1 minute ) . Signed write informed consent obtain prior inclusion study . Subjects willing adhere protocol study requirement entire study duration . Subjects abnormalities general physical examination . Exclusion criterion : Subjects incapable give informed consent study . Subjects SeDBP &gt; = 110mmHg / SeSBP &gt; = 180 mmHg measure Doctor 's office screening randomization visit Subjects difference &gt; 8 mmHg 2 3 SeDBP measurement either screen randomization . Subjects antihypertensive therapy unable discontinue antihypertensive therapy safely period least 2 week require protocol . Subjects discontinue medication prohibit protocol . Subjects combination therapy treatment hypertension . Subjects know documented secondary hypertension include ( limited ) hypertension secondary coarctation aorta , hyperaldosteronism , unilateral bilateral renal artery stenosis , Cushing 's disease , pheochromocytoma , polycystic kidney disease , etc . Subjects know diabetes ( Type 1 Type 2 ) . Subjects know documented complication hypertension include ( limited ) : Cardiovascular disease : Ischemic heart disease ( angina , myocardial infarction ) , heart failure , peripheral vascular disease . Cerebrovascular disease : Stroke , cerebral hemorrhage . Ophthalmic : Retinal hemorrhage , impaired vision , retinal microaneurysms . Subjects know severe renal impairment ( creatinine clearance &lt; 30 ml/min ) calculate use CockcroftGault equation . Subjects hyperkalemia ( &gt; 5.1mmol/L ) and/or hyponatremia ( &lt; 133mmol/L ) . Subjects know severe hepatic impairment ( alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 time upper limit normal history hepatic encephalopathy , esophageal varix , portocaval shunt . Subjects clinically significant abnormality ECG Subjects clinical condition , opinion Investigator , might interfere administration Irbesartan Amlodipine evaluation study objective . Subjects know history allergy consider due study drug component , include excipients ( lactose ) preservative . Subjects know history substance abuse ( drug alcohol dependency , alcohol , stop , &lt; 20gms per day allow study period ) . Subjects know positive HIV 1 2 virus . Subjects know suspected impairment immune function , and/or receive immunosuppressive therapy , receive immunosuppressive therapy within 30 day prior study entry . Subjects received investigational drug within 30 day inclusion . Pregnant ( demonstrate positive serum ( ßHCG ) pregnancy test screen visit ) lactate female subject . Subjects partner unwilling employ adequate contraception course study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>